Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more
Chongqing Lummy Pharmaceutical - Asset Resilience Ratio
Chongqing Lummy Pharmaceutical (300006) has an Asset Resilience Ratio of -0.19% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2022)
This chart shows how Chongqing Lummy Pharmaceutical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chongqing Lummy Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-5.53 Million | -0.19% |
| Total Liquid Assets | CN¥-5.53 Million | -0.19% |
Asset Resilience Insights
- Limited Liquidity: Chongqing Lummy Pharmaceutical maintains only -0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Chongqing Lummy Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Chongqing Lummy Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Chongqing Lummy Pharmaceutical (2007–2022)
The table below shows the annual Asset Resilience Ratio data for Chongqing Lummy Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.29% | CN¥-8.78 Million | CN¥3.05 Billion | -0.09pp |
| 2021-12-31 | -0.20% | CN¥-5.87 Million | CN¥2.93 Billion | +0.15pp |
| 2020-12-31 | -0.35% | CN¥-11.00 Million | CN¥3.15 Billion | -0.01pp |
| 2019-12-31 | -0.34% | CN¥-11.81 Million | CN¥3.50 Billion | +0.03pp |
| 2018-12-31 | -0.37% | CN¥-11.68 Million | CN¥3.14 Billion | -0.42pp |
| 2013-12-31 | 0.05% | CN¥1.10 Million | CN¥2.18 Billion | -0.10pp |
| 2010-12-31 | 0.15% | CN¥1.33 Million | CN¥884.01 Million | -0.04pp |
| 2009-12-31 | 0.19% | CN¥1.27 Million | CN¥653.63 Million | -0.27pp |
| 2008-12-31 | 0.46% | CN¥1.23 Million | CN¥268.56 Million | -0.19pp |
| 2007-12-31 | 0.65% | CN¥1.40 Million | CN¥214.69 Million | -- |